Trials / Completed
CompletedNCT04681482
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
Effectiveness and Safety of Oral Anticoagulants Among Obese Patients With Non-Valvular Atrial Fibrillation in the Veterans Affairs Population With Medicare
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 107,383 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study is to compare all DOACs (direct oral anti-coagulants) to warfarin. However, the primary analysis will be conducted among apixaban vs warfarin patients only. If sample size permits, we will also conduct other DOAC vs warfarin and DOAC vs DOAC analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation. |
Timeline
- Start date
- 2020-11-02
- Primary completion
- 2020-11-03
- Completion
- 2020-11-03
- First posted
- 2020-12-23
- Last updated
- 2023-05-22
- Results posted
- 2021-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04681482. Inclusion in this directory is not an endorsement.